Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kedei Website

Noemi Kedei, M.D.

Selected Publications

1)  Kortum RL, Rouquette-Jazdanian AK, Miyaji M, Merrill RK, Markegard E, Pinski JM, Wesselink A, Nath NN, Alexander CP, Li W, Kedei N, Roose JP, Blumberg PM, Samelson LE, Sommers CL.
A phospholipase C-?1-independent, RasGRP1-ERK-dependent pathway drives lymphoproliferative disease in linker for activation of T cells-Y136F mutant mice.
J. Immunol. 190: 147-58, 2013.
2)  Chen JQ, Heldman MR, Herrmann MA, Kedei N, Woo W, Blumberg PM, Goldsmith PK.
Absolute quantitation of endogenous proteins with precision and accuracy using a capillary Western system.
Anal. Biochem. 442: 97-103, 2013.
3)  Kedei N, Lewin NE, Géczy T, Selezneva J, Braun DC, Chen J, Herrmann MA, Heldman MR, Lim L, Mannan P, Garfield SH, Poudel YB, Cummins TJ, Rudra A, Blumberg PM, Keck GE.
Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.
ACS Chem. Biol. 8: 767-77, 2013.
4)  Kedei N, Telek A, Michalowski AM, Kraft MB, Li W, Poudel YB, Rudra A, Petersen ME, Keck GE, Blumberg PM.
Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.
Biochem. Pharmacol. 85: 313-24, 2013.
5)  Rahman GM, Shanker S, Lewin NE, Kedei N, Hill CS, Prasad BV, Blumberg PM, Das J.
Identification of the activator-binding residues in the second cysteine-rich regulatory domain of protein kinase C? (PKC?).
Biochem. J. 451: 33-44, 2013.
6)  Song X, Lopez-Campistrous A, Sun L, Dower NA, Kedei N, Yang J, Kelsey JS, Lewin NE, Esch TE, Blumberg PM, Stone JC.
RasGRPs are targets of the anti-cancer agent ingenol-3-angelate.
PLoS ONE. 8: e72331, 2013.
7)  Geczy T, Peach ML, El Kazzouli S, Sigano DM, Kang JH, Valle CJ, Selezneva J, Woo W, Kedei N, Lewin NE, Garfield SH, Lim L, Mannan P, Marquez VE, Blumberg PM.
Molecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol ester.
J. Biol. Chem. 287: 13137-58, 2012.
8)  Keck GE, Poudel YB, Rudra A, Stephens JC, Kedei N, Lewin NE, Blumberg PM.
Role of the C8 gem-dimethyl group of bryostatin 1 on its unique pattern of biological activity.
Bioorg. Med. Chem. Lett. 22: 4084-8, 2012.
9)  Gal N, Kolusheva S, Kedei N, Telek A, Naeem TA, Lewin NE, Lim L, Mannan P, Garfield SH, El Kazzouli S, Sigano DM, Marquez VE, Blumberg PM, Jelinek R.
N-methyl-substituted fluorescent DAG-indololactone isomers exhibit dramatic differences in membrane interactions and biological activity.
Chembiochem. 12: 2331-40, 2011.
10)  Yang D, Tao J, Li L, Kedei N, Tóth ZE, Czap A, Velasquez JF, Mihova D, Michalowski AM, Yuspa SH, Blumberg PM.
RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma.
Oncogene. 30: 4590-600, 2011.
11)  Kedei N, Lubart E, Lewin NE, Telek A, Lim L, Mannan P, Garfield SH, Kraft MB, Keck GE, Kolusheva S, Jelinek R, Blumberg PM.
Some phorbol esters might partially resemble bryostatin 1 in their actions on LNCaP prostate cancer cells and U937 leukemia cells.
Chembiochem. 12: 1242-51, 2011.
12)  Kedei N, Telek A, Czap A, Lubart ES, Czifra G, Yang D, Chen J, Morrison T, Goldsmith PK, Lim L, Mannan P, Garfield SH, Kraft MB, Li W, Keck GE, Blumberg PM.
The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line.
Biochem. Pharmacol. 81: 1296-308, 2011.
13)  Raifman O, Kolusheva S, Comin MJ, Kedei N, Lewin NE, Blumberg PM, Marquez VE, Jelinek R.
Membrane anchoring of diacylglycerol lactones substituted with rigid hydrophobic acyl domains correlates with biological activities.
FEBS J. 277: 233-43, 2010.
14)  Raifman O, Kolusheva S, El Kazzouli S, Sigano DM, Kedei N, Lewin NE, Lopez-Nicolas R, Ortiz-Espin A, Gomez-Fernandez JC, Blumberg PM, Marquez VE, Corbalan-Garcia S, Jelinek R.
Membrane-surface anchoring of charged diacylglycerol-lactones correlates with biological activities.
Chembiochem. 11: 2003-9, 2010.
15)  Keck GE, Poudel YB, Rudra A, Stephens JC, Kedei N, Lewin NE, Peach ML, Blumberg PM.
Molecular modeling, total synthesis, and biological evaluations of C9-deoxy bryostatin 1.
Angew. Chem. Int. Ed. Engl. 49: 4580-4, 2010.
16)  Yang D, Kedei N, Li L, Tao J, Velasquez JF, Michalowski AM, Tóth BI, Marincsák R, Varga A, Bíró T, Yuspa SH, Blumberg PM.
RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype.
Cancer Res. 70: 7905-17, 2010.
17)  Pu Y, Garfield SH, Kedei N, Blumberg PM.
Characterization of the differential roles of the twin C1a and C1b domains of protein kinase C-delta.
J. Biol. Chem. 284: 1302-12, 2009.
18)  Comin MJ, Czifra G, Kedei N, Telek A, Lewin NE, Kolusheva S, Velasquez JF, Kobylarz R, Jelinek R, Blumberg PM, Marquez VE.
Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengths.
J. Med. Chem. 52: 3274-83, 2009.
19)  Keck GE, Poudel YB, Welch DS, Kraft MB, Truong AP, Stephens JC, Kedei N, Lewin NE, Blumberg PM.
Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters.
Org. Lett. 11: 593-6, 2009.
20)  Keck GE, Li W, Kraft MB, Kedei N, Lewin NE, Blumberg PM.
The bryostatin 1 A-ring acetate is not the critical determinant for antagonism of phorbol ester-induced biological responses.
Org. Lett. 11: 2277-80, 2009.
21)  Choi SH, Czifra G, Kedei N, Lewin NE, Lazar J, Pu Y, Marquez VE, Blumberg PM.
Characterization of the interaction of phorbol esters with the C1 domain of MRCK (myotonic dystrophy kinase-related Cdc42 binding kinase) alpha/beta.
J. Biol. Chem. 283: 10543-9, 2008.
22)  Duan D, Sigano DM, Kelley JA, Lai CC, Lewin NE, Kedei N, Peach ML, Lee J, Abeyweera TP, Rotenberg SA, Kim H, Kim YH, El Kazzouli S, Chung JU, Young HA, Young MR, Baker A, Colburn NH, Haimovitz-Friedman A, Truman JP, Parrish DA, Deschamps JR, Perry NA, Surawski RJ, Blumberg PM, Marquez VE.
Conformationally constrained analogues of diacylglycerol. 29. Cells sort diacylglycerol-lactone chemical zip codes to produce diverse and selective biological activities.
J. Med. Chem. 51: 5198-220, 2008.
23)  Keck GE, Kraft MB, Truong AP, Li W, Sanchez CC, Kedei N, Lewin NE, Blumberg PM.
Convergent Assembly of Highly Potent Analogues of Bryostatin 1 via Pyran Annulation: Bryostatin Look-Alikes That Mimic Phorbol Ester Function.
J. Am. Chem. Soc. 2008.
24)  Philosof-Mazor L, Volinsky R, Comin MJ, Lewin NE, Kedei N, Blumberg PM, Marquez VE, Jelinek R.
Self-assembly and lipid interactions of diacylglycerol lactone derivatives studied at the air/water interface.
Langmuir : the ACS journal of surfaces and colloids. 24: 11043-52, 2008.
25)  Blumberg PM, Kedei N, Lewin NE, Yang D, Czifra G, Pu Y, Peach ML, Marquez VE.
Wealth of opportunity - the C1 domain as a target for drug development.
Current drug targets. 9: 641-52, 2008.
26)  Malolanarasimhan K, Kedei N, Sigano DM, Kelley JA, Lai CC, Lewin NE, Surawski RJ, Pavlyukovets VA, Garfield SH, Wincovitch S, Blumberg PM, Marquez VE.
Conformationally constrained analogues of diacylglycerol (DAG). 27. Modulation of membrane translocation of protein kinase C (PKC) isozymes alpha and delta by diacylglycerol lactones (DAG-lactones) containing rigid-rod acyl groups.
J. Med. Chem. 50: 962-78, 2007.
27)  Lizanecz E, Bagi Z, Pásztor ET, Papp Z, Edes I, Kedei N, Blumberg PM, Tóth A.
Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1.
Mol. Pharmacol. 69: 1015-23, 2006.
28)  Pu Y, Perry NA, Yang D, Lewin NE, Kedei N, Braun DC, Choi SH, Blumberg PM, Garfield SH, Stone JC, Duan D, Marquez VE.
A novel diacylglycerol-lactone shows marked selectivity in vitro among C1 domains of protein kinase C (PKC) isoforms alpha and delta as well as selectivity for RasGRP compared with PKCalpha.
J. Biol. Chem. 280: 27329-38, 2005.
29)  Tóth A, Wang Y, Kedei N, Tran R, Pearce LV, Kang SU, Jin MK, Choi HK, Lee J, Blumberg PM.
Different vanilloid agonists cause different patterns of calcium response in CHO cells heterologously expressing rat TRPV1.
Life Sci. 76: 2921-32, 2005.
30)  Tóth A, Boczán J, Kedei N, Lizanecz E, Bagi Z, Papp Z, Edes I, Csiba L, Blumberg PM.
Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain.
Brain Res. Mol. Brain Res. 135: 162-8, 2005.
31)  Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, Shaughnessy J, Rudikoff S.
Wnts induce migration and invasion of myeloma plasma cells.
Blood. 106: 1786-93, 2005.
32)  Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM.
Characterization of the interaction of ingenol 3-angelate with protein kinase C.
Cancer Res. 64: 3243-55, 2004.
33)  Pearce LV, Petukhov PA, Szabo T, Kedei N, Bizik F, Kozikowski AP, Blumberg PM.
Evodiamine functions as an agonist for the vanilloid receptor TRPV1.
Org. Biomol. Chem. 2: 2281-6, 2004.
34)  Wang Y, Kedei N, Wang M, Wang QJ, Huppler AR, Toth A, Tran R, Blumberg PM.
Interaction between protein kinase Cmu and the vanilloid receptor type 1.
J. Biol. Chem. 279: 53674-82, 2004.
35)  Tóth A, Kedei N, Wang Y, Blumberg PM.
Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat.
Life Sci. 73: 487-98, 2003.
36)  Tóth A, Kedei N, Szabó T, Wang Y, Blumberg PM.
Thapsigargin binds to and inhibits the cloned vanilloid receptor-1.
Biochem. Biophys. Res. Commun. 293: 777-82, 2002.
37)  Kedei N, Szabo T, Lile JD, Treanor JJ, Olah Z, Iadarola MJ, Blumberg PM.
Analysis of the native quaternary structure of vanilloid receptor 1.
J. Biol. Chem. 276: 28613-9, 2001.
38)  Szondy Z, Molnar P, Nemes Z, Boyiadzis M, Kedei N, Tóth R, Fésüs L.
Differential expression of tissue transglutaminase during in vivo apoptosis of thymocytes induced via distinct signalling pathways.
FEBS Lett. 404: 307-13, 1997.
39)  Balajthy Z, Kedei N, Nagy L, Davies PJ, Fésüs L.
Lack of induction of tissue transglutaminase but activation of the preexisting enzyme in c-Myc-induced apoptosis of CHO cells.
Biochem. Biophys. Res. Commun. 236: 280-4, 1997.
40)  Schittny JC, Paulsson M, Vallan C, Burri PH, Kedei N, Aeschlimann D.
Protein cross-linking mediated by tissue transglutaminase correlates with the maturation of extracellular matrices during lung development.
Am. J. Respir. Cell Mol. Biol. 17: 334-43, 1997.
41)  Taresa E, Kedei N, Thomazy V, Fesus L.
An involucrin-like protein in hepatocytes serves as a substrate for tissue transglutaminase during apoptosis.
J. Biol. Chem. 267: 25648-51, 1992.
42)  Fesus L, Tarcsa E, Kedei N, Autuori F, Piacentini M.
Degradation of cells dying by apoptosis leads to accumulation of epsilon(gamma-glutamyl)lysine isodipeptide in culture fluid and blood.
FEBS Lett. 284: 109-12, 1991.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/9/2014.